PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL ...

Hoth Therapeutics (HOTH) announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide, or ASO, ...

The study will include multiple dose groups, detailed pathology assessments, and pharmacokinetic profiling. "These strategic milestones mark significant momentum for HT-KIT as we move toward ...

Other diagnoses in this pile include Tourette’s syndrome, dyslexia and dyspraxia, mast cell activation syndrome ... a severe form with a demonstrable pathology, like a genetic or biochemical ...

Nerve growth factor is a soluble protein released by mast cells (14), macrophages ... and clinical pathology results (blood and urine) were satisfactory. Specifically, the packed cell volume and total ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

The following is a summary of “Prevalence of Mast Cell Activation Disorders and Hereditary Alpha Tryptasemia Amongst POTS and ...

Cells with electrophysiological activity obtained at the University of the Basque Country (UPV/EHU) are opening up new ...

Scientists have attempted to map the human cell since the first microscope was invented more than 400 years ago. But many ...

For the first time, scientists have built a detailed, interactive map of a human cell, revealing how thousands of proteins ...

By mapping the subcellular architecture and protein interactions within cells, researchers can better understand how mutations contribute to pediatric cancers and other conditions.